Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design

BACKGROUND: We evaluated the safety and immunogenicity of (i) an intradermal HIV-DNA regimen given with/without intradermal electroporation (EP) as prime and (ii) the impact of boosting with modified vaccinia virus Ankara (HIV-MVA) administered with or without subtype C CN54rgp140 envelope protein a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Main Authors: Viegas, Edna O., Kroidl, Arne, Munseri, Patricia J., Missanga, Marco, Nilsson, Charlotta, Tembe, Nelson, Bauer, Asli, Joachim, Agricola, Joseph, Sarah, Mann, Philipp, Geldmacher, Christof, Fleck, Sue, Stöhr, Wolfgang, Scarlatti, Gabriella, Aboud, Said, Bakari, Muhammad, Maboko, Leonard, Hoelscher, Michael, Wahren, Britta, Robb, Merlin L., Weber, Jonathan, McCormack, Sheena, Biberfeld, Gunnel, Jani, Ilesh V., Sandström, Eric, Lyamuya, Eligius
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2018
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6264478/
https://ncbi.nlm.nih.gov/pubmed/30496299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0206838
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares